Juventas Therapeutics is focused on developing non-viral gene therapies for advanced cardiovascular diseases, with its lead candidate JVS-100 undergoing evaluation in clinical studies. JVS-100 is being developed under an exclusive license from the Cleveland Clinic. The company was founded in 2007 and is based in Cleveland, Ohio, and is led by president and CEO Rahul Aras, Ph.D. Juventas recently expanded its Board of Directors with the addition of James Boland. Financially, the company secured a financing package comprising equity and debt to support its clinical-stage programs. The financing details indicate a mix of Series B-2 equity and debt with milestone-linked additional capital available. Juventas Therapeutics, founded in 2007 and led by President & CEO Rahul Aras, Ph.D., is a Cleveland, OH-based clinical-stage regenerative medicine company advancing JVS-100, its lead product encoding Stromal cell‑Derived Factor 1 (SDF‑1). JVS-100 has been shown to repair damaged tissue by recruiting circulating stem cells to sites of injury, preventing ongoing cell death, and restoring blood flow. The company closed a $22.2M Series B financing and intends to use the funds to complete ongoing Phase II clinical trials. The Phase II trials are investigating JVS-100 in patients with chronic heart failure and critical limb ischemia, and both trials are actively enrolling. The financing supports continued clinical development of the therapy and associated programs.

Total raised

$36M

Funding rounds

3

Latest round

Debt Financing

Latest activity

May 2015